-
Mashup Score: 23Treatment Strategies for Advanced Classical Hodgkin Lymphoma in the Times of Dacarbazine Shortage - 7 month(s) ago
The shortage of dacarbazine (DTIC) has created an acute and unprecedented crisis in the management of patients with classical Hodgkin lymphoma, with DTIC being an essential component of doxorubicin, bleomycin, vinblastine, and DTIC (ABVD) and prior attempts at omitting DTIC from ABVD leading to substantial loss of efficacy. In this review, we discuss the strategies to manage classical Hodgkin lymphoma during the DTIC shortage and propose a treatment algorithm on the basis of fitness and ability to receive anthracyclines safely.
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1(1) Faculty Position: Lymphoma Service | Memorial Sloan Kettering Cancer Center | LinkedIn - 11 month(s) ago
About the job At Memorial Sloan Kettering (MSK), we’re not only changing the way we treat cancer, but also the way the world thinks about it. By working together and pushing forward with innovation and discovery, we’re driving excellence and improving outcomes. We’re treating cancer, one patient at a time. Join us and make a difference every day. In compliance…
Source: www.linkedin.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @gilles_salles: Great Opportunity at MSK: Faculty Position: Lymphoma Service https://t.co/cHIBsDnxYr
-
-
Mashup Score: 5Impact of monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: A multicenter cohort study - 11 month(s) ago
Key Points. Patients with MZL who had M-protein at diagnosis had inferior PFS compared to those with no M-proteinMZLs producing M-protein at diagnosis have a hi
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
#lymsm Ever wondered about the impact of M protein in your patients with MZL? Read our new paper spearheaded by @NEpperla @OSUCCC_James and @lymphomatic, out now in @BloodAdvances @ASH_hematology https://t.co/1E4FiEHHMh
-
-
Mashup Score: 18
/PRNewswire/ — AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved EPKINLYTM (epcoritamab-bysp), as the first…
Source: www.prnewswire.comCategories: Hem/Oncs, Latest HeadlinesTweet-
**Newsflash** #lymsm FDA approves epcoritamab for RR DLBCL >= 2L of therapy 24 h inpt stay recommended C1D15 when 1st full dose given EPKINLY™ (epcoritamab-bysp) Approved by U.S. FDA as the First and Only Bispecific Antibody to Treat Adult Patients... https://t.co/mrdaFuRZv1
-
-
Mashup Score: 2JAANA 2023 | Jipmer Alumni Association of North America - 1 year(s) ago
19th Biennial Meeting and CME October 6 and 7, 2023 Hyatt Regency Jacksonville Riverfront Jacksonville, FL Dear fellow alumni, With COVID finally behind us and in accordance with the desire of our members, we will resume our in person biennial meetings at the Hyatt Regency Jacksonville Riverfront, FL on October 6 and 7, 2023! We have arranged for a stimulating CME…
Source: jaana.jipmer.netCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @sugarkro: https://t.co/gTfyrswFTD Registration is open. #JAANA #JIPMER alumni meeting in Jacksonville! @OfficialJipmer @jipmernet pleas…
-
-
Mashup Score: 0AMG176, an MCL-1 inhibitor, is active in pre-clinical models of aggressive B-cell lymphomas - 1 year(s) ago
Upregulation of the anti-apoptotic protein MCL-1 has been implicated in chemotherapy resistance and poor clinical outcomes in B-cell lymphoma (BCL). We report the activity of AMG176, a direct, sele…
Source: Taylor & FrancisCategories: Hem/Oncs, Latest HeadlinesTweet-
#lymsm Our work on MCL-1 inhibitor, AMG176, in pre-clinical models of aggressive B-cell lymphomas is finally out! https://t.co/vPdssFyqRe We studied AMG176 in DLBCL, double-hit lymphoma (DHL) and Burkitt’s lymphoma (BL). 1/
-
-
Mashup Score: 3Coronavirus (COVID-19) Update: FDA Authorizes Changes to Simplify Use of Bivalent mRNA COVID-19 Vaccines - 1 year(s) ago
The FDA amended the EUAs of the Moderna and Pfizer-BioNTech COVID-19 bivalent mRNA vaccines to simplify the vaccination schedule for most individuals.
Categories: Hem/Oncs, Latest HeadlinesTweet-
Important info for our patients with lymphoma, especially those over 65 years. #lymsm #geriheme Coronavirus (COVID-19) Update: FDA Authorizes Changes to Simplify Use of Bivalent mRNA COVID-19 Vaccines https://t.co/G9ulGKVQUh
-
-
Mashup Score: 2Yellapragada Subbarow - Wikipedia - 1 year(s) ago
From Wikipedia, the free encyclopedia Yellapragada Subba RaoCommemorative postage stamp celebrating the birth centenary of Dr. SubbaRao (anglicized version of Subba Rao)Born12 January 1895Bhimavaram, Madras Presidency, British India(now in Andhra Pradesh, India)Died8 August 1948 (aged 53)New York City, United StatesNationalityIndianAlma materHarvard Medical SchoolMadras Medical…
Source: en.wikipedia.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
@NicoGagelmann Great thread. Would like to highlight the Indian connection here: aminopterin synthesis is credited to Dr. Yellapragada Subbarao from the Lederle group. https://t.co/mzOpHAQTm2 @nihardesai7 @PanktiMehta24
-
-
Mashup Score: 0
Pevonedistat (TAK924) is a Nedd8-activating enzyme inhibitor with preclinical activity in non-Hodgkin lymphoma (NHL). This open-label, Phase I, multicenter, investigator-sponsored study enrolled patients with relapsed/refractory (R/R) NHL and chronic lymphocytic leukemia (CLL). The primary objective was safety. Pevonedistat was given intravenously on days 1, 3, 5 of a 21-day cycle for 8 cycles at…
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet-
Nedd8 inhibition reinvigorates T-cell responses in lymphomas, in addition to NFkB inhibition. Thank you @DanilovLab for your excellent leadership on this project and our clinical trial with #pevonedistat in R/R lymphomas. https://t.co/rzx8rUEoiK #lymsm @cityofhope @RoswellPark https://t.co/e3s2MNAUPv
-
-
Mashup Score: 1
Low-dose, daily olanzapine is a simple, inexpensive, well-tolerated intervention that significantly improves appetite and weight gain in newly diagnosed patients on chemotherapy.
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
Proud of my alma mater @OfficialJipmer and the oncology team for publishing such impactful data in @JCO_ASCO with meagre resources! Randomized Double-Blind Placebo-Controlled Study of Olanzapine for Chemotherapy-Related Anorexia in Patients With L… https://t.co/VIZov49MZB https://t.co/kWYwuSNT3D
-
#lymsm #drugshortage With DACARBAZINE SHORTAGE knocking on our doors again, sharing this article I penned with @drrx4L @DrAEvens during the last shortage. @ASCO @JCO_ASCO. Managing Hodgkin lymphoma during dacarbazine shortage https://t.co/lSxXdV1tAu